

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Hematology				
Sickle cell disease	Adenosine A _{2A} receptor (ADORA _{2A})	<p>Studies in mice suggest that ADORA_{2A} agonists could help treat sickle cell disease. In a mouse model of sickle cell disease, the selective ADORA_{2A} agonist apadenoson decreased inflammatory cell accumulation in the lung and improved breathing compared with a vehicle control. Next steps include testing the safety of another ADORA_{2A} agonist, regadenoson, in patients with sickle cell disease.</p> <p>Lexiscan regadenoson, a selective ADORA_{2A} agonist, is marketed by Gilead Sciences Inc. and Astellas Pharma Inc. as a pharmaceutical stress agent for cardiovascular diagnostic imaging.</p> <p>Stedivaze apadenoson, a selective ADORA_{2A} agonist from Clinical Data Inc., is in Phase III testing as a pharmaceutical stress agent for cardiovascular diagnostic imaging.</p> <p>SciBX 3(37); doi:10.1038/scibx.2010.1120 Published online Sept. 23, 2010</p>	Unpatented; unavailable for licensing	<p>Wallace, K.L. & Linden, J. <i>et al. Blood</i>; published online Aug. 26, 2010; doi:10.1182/blood-2010-06-290643</p> <p>Contact: Joel Linden, La Jolla Institute for Allergy and Immunology, La Jolla, Calif. e-mail: jlinden@liai.org</p>